Clinical Outcomes of Later‐Generation EGFR‐TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real‐World Study

ABSTRACT Background Uncommon EGFR mutations, including G719X, L861Q, S768I, and compound mutations, present therapeutic challenges due to limited prospective evidence and variable drug sensitivity. Although later‐generation (i.e., second‐ and third‐) EGFR‐TKIs have shown benefit in some subtypes, re...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Lisa Shigematsu, Tetsuo Tani, Shinnosuke Ikemura, Keiko Ohgino, Kohei Horiuchi, Taro Shinozaki, Shigenari Nukaga, Hideki Terai, Takashi Sato, Katsuhiko Naoki, Koichi Sayama, Yoshitaka Oyamada, Fumio Sakamaki, Kenzo Soejima, Hiroyuki Yasuda, Koichi Fukunaga, Keio Lung Oncology Group (KLOG)
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2025-10-01
Schriftenreihe:	Thoracic Cancer
Schlagworte:	afatinib NSCLC osimertinib real‐world data uncommon EGFR mutations
Online-Zugang:	https://doi.org/10.1111/1759-7714.70179
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!